I. Paul Singh, MD; and Carl D. Regillo, MD
Show Description +
In this episode of Innovation Journal Club, Carl Regillo, MD, and I. Paul Singh, MD, discuss outcomes from phase 3 studies of faricimab-svoa (Vabysmo, Genentech) and aflibercept 8 mg (Eyelea HD, Regeneron) in neovascular AMD. According to Dr. Regillo, the data suggests that these agents achieve greater durability and a better drying effect than first-generation anti-VEGF drugs.
Posted: 3/01/2025
I. Paul Singh, MD; and Carl D. Regillo, MD
In this episode of Innovation Journal Club, Carl Regillo, MD, and I. Paul Singh, MD, discuss outcomes from phase 3 studies of faricimab-svoa (Vabysmo, Genentech) and aflibercept 8 mg (Eyelea HD, Regeneron) in neovascular AMD. According to Dr. Regillo, the data suggests that these agents achieve greater durability and a better drying effect than first-generation anti-VEGF drugs.
Posted: 3/01/2025
Supported by
Please log in to leave a comment.